HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sara Huerta-Yepez Selected Research

2,2'- (hydroxynitrosohydrazono)bis- ethanamine

2/2013Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer.
5/2009In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF.
2/2009Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.
9/2008Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases.
10/2005Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sara Huerta-Yepez Research Topics

Disease

45Neoplasms (Cancer)
05/2022 - 06/2004
8Prostatic Neoplasms (Prostate Cancer)
10/2017 - 06/2004
7Neoplasm Metastasis (Metastasis)
02/2022 - 09/2008
7Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2016 - 01/2005
6Hypoxia (Hypoxemia)
02/2022 - 07/2012
5Carcinoma (Carcinomatosis)
02/2013 - 06/2004
4Lung Neoplasms (Lung Cancer)
05/2022 - 06/2011
4Carcinogenesis
01/2021 - 06/2006
4B-Cell Lymphoma (Lymphoma, B Cell)
03/2019 - 10/2003
3Leukemia
02/2022 - 01/2020
3Lymphoma (Lymphomas)
01/2021 - 12/2009
3Multiple Myeloma
10/2019 - 04/2011
3Inflammation (Inflammations)
11/2013 - 04/2012
2Fibrosis (Cirrhosis)
01/2021 - 11/2013
2Infections
01/2018 - 11/2013
2Pulmonary Tuberculosis
01/2018 - 01/2016
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2016 - 01/2015
2Necrosis
01/2013 - 10/2003
2Asthma (Bronchial Asthma)
07/2012 - 04/2012
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2022
1Triple Negative Breast Neoplasms
01/2021
1Breast Neoplasms (Breast Cancer)
01/2021
1Hepatocellular Carcinoma (Hepatoma)
12/2020
1Brain Neoplasms (Brain Tumor)
06/2020
1Weight Loss (Weight Reduction)
10/2019
1Wilms Tumor (Wilm's Tumor)
04/2019
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2019
1Medulloblastoma
01/2019
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/2018
1Sepsis (Septicemia)
05/2017
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2015

Drug/Important Bio-Agent (IBA)

14Transcription Factors (Transcription Factor)IBA
02/2022 - 07/2005
13Proteins (Proteins, Gene)FDA Link
02/2022 - 10/2003
9NF-kappa B (NF-kB)IBA
02/2009 - 06/2004
8Rituximab (Mabthera)FDA Link
01/2016 - 01/2005
7Pharmaceutical PreparationsIBA
10/2019 - 01/2005
7Nitric Oxide (Nitrogen Monoxide)FDA Link
02/2013 - 06/2004
5Monoclonal AntibodiesIBA
01/2016 - 01/2005
52,2'- (hydroxynitrosohydrazono)bis- ethanamineIBA
02/2013 - 10/2005
4Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
05/2022 - 06/2020
4LigandsIBA
11/2015 - 10/2003
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2013 - 06/2004
4Nitric Oxide DonorsIBA
05/2009 - 06/2004
3Messenger RNA (mRNA)IBA
02/2022 - 07/2007
3YY1 Transcription FactorIBA
08/2021 - 05/2017
3Antineoplastic Agents (Antineoplastics)IBA
06/2020 - 02/2017
3EnzymesIBA
01/2019 - 04/2012
3Biomarkers (Surrogate Marker)IBA
11/2014 - 07/2007
3CytokinesIBA
11/2013 - 04/2012
3Proto-Oncogene Proteins c-rafIBA
04/2011 - 12/2009
3DNA (Deoxyribonucleic Acid)IBA
02/2009 - 10/2005
2OxylipinsIBA
05/2022 - 06/2020
2Fatty Acids (Saturated Fatty Acids)IBA
06/2020 - 01/2019
2fas Receptor (CD95 Antigen)IBA
01/2020 - 05/2017
2Bortezomib (Velcade)FDA Link
10/2019 - 10/2008
22-MethoxyestradiolIBA
01/2018 - 05/2013
2TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA
10/2017 - 11/2014
2Cadherins (E-Cadherin)IBA
11/2015 - 12/2010
2ChemokinesIBA
07/2012 - 04/2012
2Indicators and Reagents (Reagents)IBA
06/2011 - 10/2007
2Fas Ligand Protein (Fas Ligand)IBA
09/2006 - 10/2005
1Apoptosis Regulatory ProteinsIBA
05/2022
1Calcium-Calmodulin-Dependent Protein KinasesIBA
01/2021
1kenpaulloneIBA
01/2021
1Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
01/2021
1p21-Activated KinasesIBA
01/2021
1Peptide Hydrolases (Proteases)FDA Link
01/2021
1Epoxy Compounds (Epoxides)IBA
12/2020
1Epoxide HydrolasesIBA
12/2020
1Polychlorinated Dibenzodioxins (TCDD)IBA
12/2020
1Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
12/2020
1MicroRNAs (MicroRNA)IBA
01/2020
1Proteasome InhibitorsIBA
10/2019
1Mechanistic Target of Rapamycin Complex 1IBA
10/2019
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2019
1IfosfamideFDA LinkGeneric
01/2019
1Cytochrome P-450 CYP2B6 (CYP2B6)IBA
01/2019
1Histones (Histone)IBA
01/2019
1Biological ProductsIBA
01/2019
1Glucose (Dextrose)FDA LinkGeneric
01/2019
1Cytochrome P-450 CYP3AIBA
01/2019
1Lysine (L-Lysine)FDA Link
01/2019
1MethyltransferasesIBA
01/2019
1CytochromesIBA
01/2019
1Hypoxia-Inducible Factor 1IBA
01/2018
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
02/2017
1sulforaphaneIBA
02/2017
1Retinoic Acid Receptor alphaIBA
12/2016
1Chemokine CCL4IBA
01/2016
1VimentinIBA
11/2015
1Corticotropin-Releasing HormoneIBA
11/2015
1p38 Mitogen-Activated Protein KinasesIBA
10/2015
1Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
01/2015
1Oncogene Proteins (Oncogene Protein)IBA
02/2014
1EpitopesIBA
02/2014
1AntibodiesIBA
02/2014

Therapy/Procedure

12Therapeutics
01/2021 - 06/2006
8Drug Therapy (Chemotherapy)
11/2018 - 08/2005
4Immunotherapy
01/2016 - 10/2007
2Chemoprevention
01/2021 - 06/2006